Highlights: BioXcel Therapeutics

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses: BioXcel Therapeutics

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings Chart: BioXcel Therapeutics

Source: Surperformance

ESG chart: BioXcel Therapeutics

Source: MSCI
Investor
-
Trader
ESG MSCI
BB

Financials

Sales growth
EPS Growth
Profitability
-
Net margin
-
Financial Health
-

Valuation

P/E ratio
-
EV/REVENUE
EV/EBITDA
-
PBR
-
Yield
-

Revisions

1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision

Business Predictability

Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions

ESG

Environment
Social
Governance
Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
Sharia compliant
-
  1. Stock Market
  2. Equities
  3. BTAI Stock
  4. Ratings BioXcel Therapeutics